Ichthyosis Vulgaris

Clinical guidelines for managing keratinization disorders, evaluating FLG mutations and filaggrin/NMF deficiency, and reviewing humectants and barrier recovery.

⏱️ 4 min read

Table of Contents

🧠 Standard of Care & Symptoms

Ichthyosis Vulgaris is the most common form of inherited ichthyosis, characterized by an autosomal dominant impairment of epidermal barrier function and skin hydration.

🧬 Diagnostics & FLG Filaggrin Deficiency

Diagnosis is established clinically based on extensor scaling with flexural sparing, and confirmed by skin biopsy and molecular analysis.

Pathogenesis & Natural Moisturizing Factor (NMF) Depletion

The skin peeling and severe dryness in Ichthyosis Vulgaris are driven by the loss of a key structural scaffold and humectant precursor:

πŸ’Š Keratolytics, Humectants & Barrier Restorers

Management focuses on removing excess scaling (keratolysis), drawing water into the stratum corneum (humectants), and sealing the barrier (occlusion).

Exfoliation and Desquamation

Barrier Protection and Lifestyle

πŸ”¬ Active Clinical Trials

Clinical trials are currently evaluating next-generation Th2 path inhibitors to manage concurrent eczema, topical filaggrin peptide replacement therapies, and novel humectant vehicles.

NCT06922799: Topical Filaggrin Replacement Peptide (FLG-102)

Evaluating the efficacy of a lipid-nanoparticle topical gel containing synthetic filaggrin monomers designed to penetrate the stratum corneum.

Key Inclusion: Age ≥ 18, genetically confirmed FLG mutation, and baseline moderate-to-severe extensor scaling.
NCT07050595: Dupilumab for Ichthyosis Vulgaris and Atopic Diathesis

A Phase II trial studying whether systemic Th2 blockade improves skin barrier properties and reduces scaling in patients with dual diagnoses of HHD/IV and eczema.

Key Inclusion: Age ≥ 12, diagnosed with both ichthyosis vulgaris and atopic dermatitis, and failed topical treatments.
NCT07119599: High-Strength Urea (20%) Foam Optimization Study

Testing the safety, tolerability, and scaling reduction of a new daily 20% urea foam formulation for palmoplantar hyperlinearity and scaling.

Key Inclusion: Age ≥ 18, diagnosed with classical ichthyosis vulgaris, and severe palmoplantar skin thickening.
Important: Browse actively recruiting clinical trials in our Clinical Trials Catalogue to find a local study.

πŸ—ΊοΈ Next Steps After Diagnosis

If you have recently been diagnosed with Ichthyosis Vulgaris, establish these care plans:

  1. Verify Granular Layer Status: Ensure skin biopsy shows a reduced granular layer to confirm ichthyosis vulgaris over other scaling diseases.
  2. Order FLG gene testing: Confirm loss-of-function mutations and evaluate risk for other atopic allergies.
  3. Start Topical humectants: Discuss starting Ammonium Lactate 12% or Urea creams with your physician to promote scaling clearance.
  4. Adopt the "Soak and Smear" routine: Apply thick Petrolatum ointments immediately after bathing to restore moisture.

❓ Patient FAQ

Q: What is "flexural sparing" in Ichthyosis Vulgaris?
A: "Flexural sparing" means that the scaling and dryness do not affect the skin folds and creases of your body, such as the armpits, the front of the elbows, and the back of the knees. In these folds, the skin remains completely normal, soft, and healthy. This sparing is a key feature that helps doctors distinguish Ichthyosis Vulgaris from other skin scaling disorders (like Lamellar Ichthyosis, which affects the entire body including the folds).

Q: What is the relationship between filaggrin and dry skin?
A: Filaggrin is a protein that serves two critical roles in keeping skin healthy. First, it binds skin structural proteins together to flatten and seal the cells, forming a strong outer barrier. Second, as these skin cells mature, filaggrin is broken down into **Natural Moisturizing Factors (NMFs)**. NMFs are natural sponge-like molecules that absorb and hold water to keep the skin hydrated. In Ichthyosis Vulgaris, a mutation in the **FLG** gene causes a shortage of filaggrin, which leads to a loss of NMFs, causing the skin to dehydrate, crack, and scale.

Get the Free 2026 Clinical AI Directory

Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.

Request Directory via Email